

Technological Innovation Portfolio, Series 14

Investment Objective

The Technological Innovation Portfolio, Series 14 (Trust) seeks to provide the potential for capital appreciation.


Key Considerations

- **Growth Opportunities:** Technologically innovative companies are leveraging current or generating new technologies to create growth opportunities.
- **Outperformance Potential:** Guggenheim believes innovative companies have the potential to outperform the broader market.
- **Diversified Innovation:** Seeks to allow investors the opportunity to gain exposure to companies who have demonstrated innovation in fields such as health sciences, global security, information access, and manufacturing improvements.

Portfolio Allocation

Breakdown and weightings are as of 9.27.2019 and subject to change.

CAPITALIZATION BREAKDOWN




COUNTRY WEIGHTINGS (HEADQUARTERED)

United States	85.66%
Ireland	3.61%
Canada	3.60%
Israel	3.57%
France	3.56%
Total	100.00%

The Impact of Technology

Technological innovations are changing the business landscape, demanding that businesses grow, shift and adapt in order to stay competitive. To position themselves for the future, many companies are increasing spending on emerging technologies. According to the International Data Corporation, the U.S. market is expected to post some of the strongest growth rates in information and communication technologies spending, in spite of its relative maturity, led by digital transformation, cloud and AI investments¹. The Trust's portfolio provides investors access to the technologies that Guggenheim believes have the greatest potential to benefit from increased spending. The chart below shows the forecasted worldwide spending for five of these innovative technology sectors.



Past performance is not a guarantee of future results. There is no guarantee that the trends and projections noted above will continue or come to fruition and they are subject to change. Source: International Data Corporation ¹2.4.2019 ²2.28.2019 ³4.4.2019 ⁴3.20.2019 ⁵1.8.2019 ⁶12.4.2018.

Access to Emerging Technologies

The portfolio offers broad exposure to seven identified segments of the market where Guggenheim believes significant technological innovation and growth are occurring:



Cloud Computing is the delivery of on-demand hardware and software via the Internet. Cloud computing is a leading trend in the technology sector and has the potential to experience significant growth for years to come.



Big Data refers to extremely large data sets that can be analyzed to reveal patterns, trends, and associations. Big data is being used in many fields, including meteorology, genomics, physics, biological and environmental research.



Personalized Medicine is the mapping and harnessing of the human genome for customized preventative medicine and treatment.



Cybersecurity is the protection of information, data and systems from increasingly frequent unauthorized access and disruption.



Customized Manufacturing uses 3-D printing to create a three-dimensional solid object that replicates the design of a digital model.



Digitization is the integration of digital technologies into everyday life, including digital print media, books, music and movies for the purpose of easier storage, access and transmittal.



Robotics is the creation of robotic capital equipment to fuel more efficient processes for businesses and individuals.

Source: Guggenheim Investments.

Technological Innovation Portfolio, Series 14

PORTFOLIO HOLDINGS

Holdings, breakdown, and weightings are as of 9.27.2019 and subject to change.

Symbol	Company Name
Big Data (7.16%)	
SPLK	Splunk, Inc.
WDC	Western Digital Corporation
Cloud Computing (31.80%)	
ATVI	Activision Blizzard, Inc.
ADBE	Adobe, Inc.
GOOGL	Alphabet, Inc.
AMZN	Amazon.com, Inc.
FB	Facebook, Inc.
MSFT	Microsoft Corporation
OTEX	Open Text Corporation
ORCL	Oracle Corporation

Symbol	Company Name
CRM	salesforce.com, inc.
Custom Manufacturing (3.56%)	
DASTY	Dassault Systemes SE
Cybersecurity (14.19%)	
CHKP	Check Point Software Technologies Limited
FTNT	Fortinet, Inc.
PANW	Palo Alto Networks, Inc.
PFPT	Proofpoint, Inc.
Digitization (14.26%)	
ACN	Accenture PLC
AAPL	Apple, Inc.
CSCO	Cisco Systems, Inc.

Symbol	Company Name
JCOM	j2 Global, Inc.
Personalized Medicine (21.75%)	
DXCM	DexCom, Inc.
ILMN	Illumina, Inc.
INCY	Incyte Corporation
TMO	Thermo Fisher Scientific, Inc.
VAR	Varian Medical Systems, Inc.
VRTX	Vertex Pharmaceuticals, Inc.
Robotics (7.28%)	
ISRG	Intuitive Surgical, Inc.
ROK	Rockwell Automation, Inc.

PORTFOLIO SUMMARY

Inception Date	9.30.2019
Termination Date	9.30.2021
Initial Offer Price	\$10.00
Number of Issues	28
Historical Annual Dividend Distribution⁷	\$0.0415
Distributions	25th day of each month commencing on 10.25.2019, if any

⁷ The Historical Annual Dividend Distribution (HADD) is as of 9.27.2019 and subject to change. There is no guarantee the issuers of the securities included in the Trust will declare dividends or distributions in the future. The HADD of the securities included in the Trust is for illustrative purposes only and is not indicative of the Trust's distribution rate. The HADD is the weighted average of the trailing twelve-month distributions paid by the securities included in the portfolio and is reduced to account for the effects of fees and expenses, which will be incurred when investing in the Trust. The HADD will vary due to certain factors that may include, but are not limited to, a change in the dividends paid by issuers, a change in Trust expenses or the sale or maturity of securities in the portfolio.

SALES CHARGES

Sales Charge (S/C) is based on a \$10 per unit offering price.

Standard Accounts	Amount Per Unit	Percentage of Public Offering Price
Deferred S/C⁸	\$0.225	2.25%
Creation and Development (C&D) Fee	\$0.050	0.50%
Total S/C	\$0.275	2.75%

Fee/Wrap Accounts⁹

Creation and Development (C&D) Fee	\$0.050	0.50%
Total S/C	\$0.050	0.50%

TICKETING INFORMATION

CUSIP (cash payment)	40175B308
CUSIP (reinvestment accounts)	40175B316
CUSIP (fee-cash)	40175B324
CUSIP (fee-reinvest)	40175B332
Ticker	CATENX

⁸ The deferred sales charge (DSC) is a fixed amount and will be deducted in monthly installments on the last business day commencing April 2020 and ending June 2020 or upon early redemption. For unit prices other than \$10, percentages of C&D fees, and DSCs will vary but in no event will the maximum sales charge (S/C) exceed the total S/C. Early redemption of units will still cause payment of the DSC. However, an initial sales charge, which is equal to the difference between the maximum S/C and the sum of any remaining deferred S/C charges and C&D, will be charged if the price paid for units exceeds \$10 per unit.

⁹ For unit prices other than \$10, percentage of the C&D fee will vary.

The Technological Innovation Portfolio, Series 14 is a Unit Investment Trust.

RISK CONSIDERATIONS: As with all investments, you may lose some or all of your investment in the Trust. No assurance can be given that the Trust's investment objective will be achieved. The Trust also might not perform as well as you expect. This can happen for reasons such as these: • Securities prices can be volatile. • The Trust is concentrated in the information technology sector. The factors that impact the information technology sector will likely have a greater effect on this Trust than on a more broadly diversified trust. Companies involved in this sector must contend with rapid changes in technology, intense competition, government regulation and the rapid obsolescence of products and services. Sector predictions may not materialize and the companies selected for the Trust may not represent the entire sector and may not participate in the overall sector growth. • The Trust is concentrated in the health care sector. The factors that impact the health care sector will likely have a greater effect on this Trust than on a more broadly diversified trust. General risks of companies in the health care sector include extensive competition, generic drug sales, the loss of patent protection, product liability litigation and increased government regulation. • The Trust invests in U.S.-listed foreign securities and an ADR, which presents

additional risk. ADRs are issued by a bank or trust company to evidence ownership of underlying securities issued by foreign corporations. Securities of foreign issuers present risks beyond those of domestic securities. Foreign risk is the risk that foreign securities will be more volatile than U.S. securities due to such factors as adverse economic, currency, political, social or regulatory developments in a country. • The Trust invests in securities issued by small- and mid-cap companies, which may have limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments. These securities customarily involve more investment risk than securities of large-capitalization companies. • Share prices or dividend rates on the securities in the Trust may decline during the life of the Trust. • Inflation may lead to a decrease in the value of assets or income from investments. **Please see the Trust prospectus for more complete risk information.**

Unit Investment Trusts are fixed, not actively managed and should be considered as part of a long-term strategy. Investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. UITs are subject to annual fund operating expenses in addition to the sales charge. Investors should consult an attorney or tax advisor regarding tax consequences associated with an investment from one series to the next, if available, and with the

purchase or sale of units. Guggenheim Funds Distributors, LLC does not offer tax advice.

This material is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation.

Read the Trust's prospectus carefully before investing. It contains the Trust's investment objectives, risks, charges, expenses and other information, which should be considered carefully before investing. Obtain a prospectus at GuggenheimInvestments.com.

Guggenheim Funds Distributors, LLC

Member FINRA/SIPC

9/2019 UIT-FCT-ATEC-014 #40255